Cornell Startups
New Businesses Founded on Licensed Cornell Technologies During FY2015

Apnostics, LLC
Lawrenceville, GA
Obstructive sleep apnea (OSA) is a condition that involves multiple episodes of airway closure and/or reduction in airflow that affects 2-4% of the population. Traditionally, sleep apnea has been assessed via a nighttime polysomnogram. Apnostics will commercialize a device and method for diagnosing sleep apnea without an overnight stay in a sleep clinic using oximetry data (oxygen saturation in the blood).

BrainWire Technologies, LLC
White Plains, NY
BrainWire Technologies is a healthcare technology company aiming to develop and commercialize software that analyzes medical images to distinguish between different neurodegenerative diseases and predict the course of the disease.

Claymore Technologies, Inc.
New York, NY
Claymore Technologies, Inc. is a clinical stage biotech company focused on developing Cornell dots ("C-dot"): ultra-small, targeted, multimodal nanotechnology for the detection, real-time visualization and treatment of cancer. C-dot nanoparticles are silica particles that can be produced in a variety of nanometer sizes with narrow size distributions. They can be functionalized with biomolecules and compounds to allow particle tracking and/or drug delivery.

Conamix, Inc.
Ithaca, NY
Conamix is commercializing high performance battery materials based on proprietary Cornell technology. The company’s unique battery materials allow higher energy density in existing lithium ion architectures and are manufactured using low cost and highly commercial methods.

Guangda Cooperation International Technology Center, Co Ltd (GCITC)
Shenzhen, China
Guangda Cooperation International Technology Center will commercialize technologies for nutraceutical and nutritional food in China.

HemoGenyx, LLC
Buffalo, NY
HemoGenyx is a biopharmaceutical company developing a new treatment for blood diseases, such as leukemia, lymphoma and bone marrow ("BM") failure. The company leverages a special class of cells that can generate cancer-free, patient-matched blood stem cells.

iCareDx, Inc.
New York, NY
iCareDx is developing novel diagnostic tests to enable low-cost and accurate early detection of colorectal cancer directly from the blood, by isolating and identifying multiple cancer markers. Thus, allowing for improved sensitivity, specificity, and scalability.

Lumendi, Ltd.
London, United Kingdom
Lumendi is developing new surgical tools that can be used with commercially available endoscopes for the purpose of performing minimally invasive gastrointestinal surgeries. These tools will allow for improvements in patient outcomes by reducing anesthesia time, minimizing tissue removal and reducing hospital stays.

Lumidyne Technologies
New York, NY
Lumidyne offers a suite of organic fluorophores, which absorb and emit light in response to excitation, to provide an essential means of detecting a diverse range of target molecules and biological processes. The company’s new fluorophores have been optimized for increased brightness, longevity and time resolution.

Nirenberg Neuroscience, LLC
New York, NY
Nirenberg Neuroscience develops non-prosthetic applications of “virtual retina” software for treating blindness.

Sphaira Aneurysm Solutions, Ltd.
Jerusalem, Israel
Sphaira Aneurysm Solutions is developing minimally invasive devices for the treatment of intracranial aneurysms. The device is based on novel flow properties and will reduce blood flow into the aneurysm, decreasing the likelihood that the aneurysm will rupture. It will also facilitate clotting and vessel remodeling.

Waltz Networks, Inc.
Ithaca, NY
Waltz was founded with the goal of creating automatic, high performance network traffic management for the cloud era. Using Waltz’s platform, engineers can virtually stress test their networks and directly deploy to production their self-optimizing traffic engineering algorithms to automate network management.

XyloCor, Therapeutics, Inc.
New York, NY
XyloCor is a clinical-stage biotechnology company dedicated to developing first-in-class gene therapies for patients with cardiovascular disease. The company’s lead product comprises the use of vascular endothelial growth factor for the treatment of diffuse coronary artery disease.

For More Information Contact:
Laura Salter at LC12@cornell.edu or 607-254-4557